Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles

Megan A. Hatlen, Kanika Arora, Vladimir Vacic, Ewa A. Grabowska, Willey Liao, Bridget Riley-Gillis, Dayna M. Oschwald, Lan Wang, Jacob E. Joergens, Alan H. Shih, Franck Rapaport, Shengqing Gu, Francesca Voza, Takashi Asai, Benjamin G. Neel, Michael G. Kharas, Mithat Gonen, Ross L. Levine, Stephen D Nimer

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

t(8;21) is one of the most frequent chromosomal abnormalities observed in acute myeloid leukemia (AML). However, expression of AML1-ETO is not sufficient to induce transformation in vivo. Consistent with this observation, patients with this translocation harbor additional genetic abnormalities, suggesting a requirement for cooperating mutations. To better define the genetic landscape in AML and distinguish driver from passenger mutations, we compared the mutational profiles of AML1-ETO-driven mouse models of leukemia with the mutational profiles of human AML patients. We identified TET2 and PTPN11 mutations in both mouse and human AML and then demonstrated the ability of Tet2 loss and PTPN11 D61Y to initiate leukemogenesis in concert with expression of AML1-ETO in vivo. This integrative genetic profiling approach allowed us to accurately predict cooperating events in t(8;21)+ AML in a robust and unbiased manner, while also revealing functional convergence in mouse and human AML.

Original languageEnglish (US)
Pages (from-to)25-34
Number of pages10
JournalJournal of Experimental Medicine
Volume213
Issue number1
DOIs
StatePublished - 2016

Fingerprint

Acute Myeloid Leukemia
Alleles
Mutation
Chromosome Aberrations
Leukemia

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. / Hatlen, Megan A.; Arora, Kanika; Vacic, Vladimir; Grabowska, Ewa A.; Liao, Willey; Riley-Gillis, Bridget; Oschwald, Dayna M.; Wang, Lan; Joergens, Jacob E.; Shih, Alan H.; Rapaport, Franck; Gu, Shengqing; Voza, Francesca; Asai, Takashi; Neel, Benjamin G.; Kharas, Michael G.; Gonen, Mithat; Levine, Ross L.; Nimer, Stephen D.

In: Journal of Experimental Medicine, Vol. 213, No. 1, 2016, p. 25-34.

Research output: Contribution to journalArticle

Hatlen, MA, Arora, K, Vacic, V, Grabowska, EA, Liao, W, Riley-Gillis, B, Oschwald, DM, Wang, L, Joergens, JE, Shih, AH, Rapaport, F, Gu, S, Voza, F, Asai, T, Neel, BG, Kharas, MG, Gonen, M, Levine, RL & Nimer, SD 2016, 'Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles', Journal of Experimental Medicine, vol. 213, no. 1, pp. 25-34. https://doi.org/10.1084/jem.20150524
Hatlen, Megan A. ; Arora, Kanika ; Vacic, Vladimir ; Grabowska, Ewa A. ; Liao, Willey ; Riley-Gillis, Bridget ; Oschwald, Dayna M. ; Wang, Lan ; Joergens, Jacob E. ; Shih, Alan H. ; Rapaport, Franck ; Gu, Shengqing ; Voza, Francesca ; Asai, Takashi ; Neel, Benjamin G. ; Kharas, Michael G. ; Gonen, Mithat ; Levine, Ross L. ; Nimer, Stephen D. / Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. In: Journal of Experimental Medicine. 2016 ; Vol. 213, No. 1. pp. 25-34.
@article{e3df2be5d2fd4c2fafd2e9878d5108c9,
title = "Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles",
abstract = "t(8;21) is one of the most frequent chromosomal abnormalities observed in acute myeloid leukemia (AML). However, expression of AML1-ETO is not sufficient to induce transformation in vivo. Consistent with this observation, patients with this translocation harbor additional genetic abnormalities, suggesting a requirement for cooperating mutations. To better define the genetic landscape in AML and distinguish driver from passenger mutations, we compared the mutational profiles of AML1-ETO-driven mouse models of leukemia with the mutational profiles of human AML patients. We identified TET2 and PTPN11 mutations in both mouse and human AML and then demonstrated the ability of Tet2 loss and PTPN11 D61Y to initiate leukemogenesis in concert with expression of AML1-ETO in vivo. This integrative genetic profiling approach allowed us to accurately predict cooperating events in t(8;21)+ AML in a robust and unbiased manner, while also revealing functional convergence in mouse and human AML.",
author = "Hatlen, {Megan A.} and Kanika Arora and Vladimir Vacic and Grabowska, {Ewa A.} and Willey Liao and Bridget Riley-Gillis and Oschwald, {Dayna M.} and Lan Wang and Joergens, {Jacob E.} and Shih, {Alan H.} and Franck Rapaport and Shengqing Gu and Francesca Voza and Takashi Asai and Neel, {Benjamin G.} and Kharas, {Michael G.} and Mithat Gonen and Levine, {Ross L.} and Nimer, {Stephen D}",
year = "2016",
doi = "10.1084/jem.20150524",
language = "English (US)",
volume = "213",
pages = "25--34",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "1",

}

TY - JOUR

T1 - Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles

AU - Hatlen, Megan A.

AU - Arora, Kanika

AU - Vacic, Vladimir

AU - Grabowska, Ewa A.

AU - Liao, Willey

AU - Riley-Gillis, Bridget

AU - Oschwald, Dayna M.

AU - Wang, Lan

AU - Joergens, Jacob E.

AU - Shih, Alan H.

AU - Rapaport, Franck

AU - Gu, Shengqing

AU - Voza, Francesca

AU - Asai, Takashi

AU - Neel, Benjamin G.

AU - Kharas, Michael G.

AU - Gonen, Mithat

AU - Levine, Ross L.

AU - Nimer, Stephen D

PY - 2016

Y1 - 2016

N2 - t(8;21) is one of the most frequent chromosomal abnormalities observed in acute myeloid leukemia (AML). However, expression of AML1-ETO is not sufficient to induce transformation in vivo. Consistent with this observation, patients with this translocation harbor additional genetic abnormalities, suggesting a requirement for cooperating mutations. To better define the genetic landscape in AML and distinguish driver from passenger mutations, we compared the mutational profiles of AML1-ETO-driven mouse models of leukemia with the mutational profiles of human AML patients. We identified TET2 and PTPN11 mutations in both mouse and human AML and then demonstrated the ability of Tet2 loss and PTPN11 D61Y to initiate leukemogenesis in concert with expression of AML1-ETO in vivo. This integrative genetic profiling approach allowed us to accurately predict cooperating events in t(8;21)+ AML in a robust and unbiased manner, while also revealing functional convergence in mouse and human AML.

AB - t(8;21) is one of the most frequent chromosomal abnormalities observed in acute myeloid leukemia (AML). However, expression of AML1-ETO is not sufficient to induce transformation in vivo. Consistent with this observation, patients with this translocation harbor additional genetic abnormalities, suggesting a requirement for cooperating mutations. To better define the genetic landscape in AML and distinguish driver from passenger mutations, we compared the mutational profiles of AML1-ETO-driven mouse models of leukemia with the mutational profiles of human AML patients. We identified TET2 and PTPN11 mutations in both mouse and human AML and then demonstrated the ability of Tet2 loss and PTPN11 D61Y to initiate leukemogenesis in concert with expression of AML1-ETO in vivo. This integrative genetic profiling approach allowed us to accurately predict cooperating events in t(8;21)+ AML in a robust and unbiased manner, while also revealing functional convergence in mouse and human AML.

UR - http://www.scopus.com/inward/record.url?scp=84961155186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961155186&partnerID=8YFLogxK

U2 - 10.1084/jem.20150524

DO - 10.1084/jem.20150524

M3 - Article

C2 - 26666262

AN - SCOPUS:84961155186

VL - 213

SP - 25

EP - 34

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 1

ER -